Why the Noxopharm (ASX:NOX) share price is bouncing up today

The Noxopharm share price is up more than 7% today on release of the company's December 2020 quarterly results. Let's take a closer look.

| More on:
Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX:NOX) share price launched up more than 7% today as the company released its report for the fourth quarter December 2020.

At the time of writing, the Noxopharm share price trading up 7.69% at 63 cents.

Let's take a closer look at the clinical stage drug development company and what we learned from today's announcement.

What's lifting the Noxapharm share price today?

Noxopharm told the market today that it received $21.4 million net from the issue of shares during the December quarter. Another $201,000 was gained from shareholders exercising options. This resulted in cash reserves totalling $22.9 million at the end of the quarter.

The company spent a significantly less amount of money on operating activities for the period. Noxopharm reports that net cash used in operating activities during the December quarter amounted to $2.6 million, compared to $3.3 million in the September quarter.

Research and development (R&D) activity costs also dropped down in the December quarter coming in at $1.4 million, compared to $1.6 million for the September quarter.

Looking ahead, Noxopharm expects to receive a cash rebate in excess of $4 million coming from the Federal Government's R&D tax incentive rebate scheme.

More about Noxopharm 

Noxapharm's primary focus is on the development of Veyonda to boost the effectiveness of all 3 current methods of cancer treatment: immune-oncology therapy, radiotherapy and chemotherapy.

The company currently has two major clinical programs under way – the DARRT program and the LuPIN program.

According to Noxopharm, the purpose of the programs is "to establish Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer".

The Noxopharm share price skyrocketed 14% earlier this month on news that Veyonda is emerging as a major new treatment based on its ability to support all current methods of cancer treatment.

In addition to the DARRT and LuPIN programs, the company is planning to recruit for a third study, IONIC. Furthermore, Noxopharm's NOXCOVID-1 study has also been progressing.

Should you invest $1,000 in Noxopharm Limited right now?

Before you buy Noxopharm Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Noxopharm Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy finish to the week for ASX shares this Friday.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.
Share Market News

ASX shares in April: 8 key takeaways according to Macquarie

Here are eight key takeaways from April, according to a new note from the broker.

Read more »

Woman looking at a phone with stock market bars in the background.
Share Market News

Market outlook: Should I 'sell in May and go away'?

May is the time to sell... If you believe in fairytales.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

5 ASX All Ords stocks rocketing higher this week

Investors sent these five ASX All Ords stocks soaring this week. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Block, Corporate Travel Management, Judo, and Zip shares are sinking today

These shares are missing out on the good times on Friday. But why?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today

These shares are having a good finish to the week. Let's find out why.

Read more »

A shocked man holding some documents in the living room.
Broker Notes

Macquarie's take on Judo Capital shares after suddenly falling 19% yesterday?

Judo Bank was the ASX's top-performing banking stock in 2024.

Read more »